2 completed, 1 withdrawn. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Withdrawn 1 |
Follow Zogenix MDS, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) MT1621 - Thymidine Kinase 2 Deficiency | Phase 3 | Withdrawn | Zogenix MDS, Inc. | 2022-09-30 | 2023-09-01 | |
| A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency Observational retrospective data - Thymidine Kinase 2 Deficiency | Completed | Zogenix MDS, Inc. | 61 | 2021-07-23 | 2023-09-01 | |
| A RETROspective Study of Patients With TK2d dC/dT - Thymidine Kinase 2 (TK2) | Completed | Zogenix MDS, Inc. | 38 | 2018-11-19 | 2023-09-01 |
Muscle Weakness (3) · Mitochondrial Diseases (2) · Muscular Atrophy (2) · Blepharoptosis (1) · Deglutition Disorders (1) · Muscle Hypotonia (1) · Muscular Diseases (1)
Deoxycytidine (2) · Thymidine (2)
Spain (2) · United States (2) · Israel (1) · Russia (1) · Turkey (Türkiye) (1)